For over a decade, Genzyme and our parent company Sanofi have each been working to develop novel treatments for relapsing/remitting MS. We have integrated these two programs within Genzyme to establish ourselves as a leader in MS. Since that time, we have established a portfolio of MS therapies including two registered MS treatments.
In addition, we continue to conduct cutting-edge research in MS, focusing on developing medicines to repair the damaged immune system and treat progressive MS.
What is Multiple Sclerosis?
Multiple Sclerosis is a chronic disease of the central nervous system that affects each person differently, with symptoms ranging from numbness in the limbs to paralysis and loss of vision. MS is caused when the body’s immune system attacks the central nervous system, damaging the myelin sheath – the protective layer covering the nerves that carry signals between the brain and spinal cord and the rest of the body.
More about Multiple Sclerosis
Finding effective treatments for a complex disease like Multiple Sclerosis is no easy task, so we have ensured that our MS research is spearheaded by top experts, employing some of the most advanced and creative scientific problem-solving skills in the industry.
We recognise that truly personalised medicine involves developing relationships with patients and caregivers, health care providers, and disease organisations and foundations. We have built our MS therapy group on the same core principle that has guided our company from the beginning: the importance of deeply understanding the experiences, challenges, and triumphs of those living with a disease. We aim to foster close connections with patient organisations to best understand the needs of patients and their families, and to deliver services that have a positive impact.